News Focus
News Focus
Replies to #49022 on Biotech Values
icon url

Biowatch

06/27/07 3:51 PM

#49028 RE: DewDiligence #49022

SRDX/MRK I thought $20 million upfront was small change from your viewpoint, especially when coupled with the option to walk away.

Yes, I concede that it sounds like sour grapes on my part, and the MRK/PYY deal is not the only one you've criticized for having a minimal upfront commitment.

Clearly MRK wants to take the SRDX technology for a test drive, and if it works it could open many pathways, but I wonder what the terms are if they score a hit.

P.S., SRDX is up around 42% in 2007, so they haven't been a sleeper stock...
icon url

EyeGuy

06/27/07 9:48 PM

#49036 RE: DewDiligence #49022

Sirna-027

Sirna-027 is licensed exclusively to Allergan, so unlikely Merck has any rights to put it into a device.